Analysis of the efficacy and adverse reactions of aripiprazole and risperidone in the treatment of schizophrenia
Objective To explore the clinical effects of aripiprazole and risperidone in the treatment of schizo-phrenia.Methods Case data were collected and filed from October 2021 to October 2022.A total of 100 patients with schizophrenia admitted to the hospital were included.The participants were divided into a control group(treated with risperidone)and an observation group(treated with aripiprazole)based on a standardized random number table method,with 50 patients included in each group.Observe and compare the clinical efficacy,incidence of adverse re-actions,positive and negative symptom scale(PANSS)scores,glucose and lipid metabolism indicators,and serum prolactin levels between two groups.Results There was no significant difference in the total effective rate between the two groups(P＞0.05).Compared with before treatment,the PANSS scores of both groups decreased after treatment(P＜0.05),and there was no significant difference between the two groups in terms of PANSS scores before and after treatment(P＞0.05).The levels of TC,TG,and FPG in the control group after treatment were higher than those in the observation group before and during the same period of treatment(P＞0.05).The serum prolactin levels in the control group increased at 4,8,and 12 weeks of treatment,and were higher than those in the observation group(P＜0.05).Comparison of the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The risperidone and aripiprazole to treat schizophrenia has a comparable therapeutic effect and guaranteed safety,but aripiprazole has a relatively small impact on glycolipid metabolism and prolactin levels.
NETL
NSTL
万方数据
